Article | September 20, 2021

Increasing mRNA Capabilities And Capacity For Growing Market Needs

Source: Cytiva

By Sebastian Almeida, Director, CMC, Akron Biotech; Lloyd Jeffs, Director, Clinical Manufacturing Solutions, Precision Nanosystems; John Harmer, Head of Marketing, Aseptic Filling, and Katarina Stenklo, Enterprise Solutions Activation Leader, Cytiva


The rapid development of innovative vaccines allowed for the pharmaceutical industry to deliver its first tools in the fight against the COVID-19 pandemic. The Moderna and Pfizer BioNTech vaccines, which offer 94% efficacy for fully vaccinated adults, both rely on messenger RNA (mRNA).

Even prior to the rise of COVID, with clinical testing of some mRNA vaccines, the ability to “program” mRNA with genetic code to treat/prevent disease has been known for decades. However, the challenges associated with transitioning mRNA into a drug product have hindered its potential.

Now, the success of the mRNA vaccine market is fueling high demand for mRNA, resulting in a critical need to address mRNA manufacturing bottlenecks. As manufacturers across the industry continue to pursue mRNA-based therapies, it is important they understand the challenges they may face in their journey and which solutions could help overcome them.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online